Compare Incyte Corporation (INCY) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Star Bulk Carriers Corp — how do they compare? Incyte Corporation trades at $113.1 (market cap $22.85B), while Star Bulk Carriers Corp trades at $29.64 (market cap $3.54B). The key difference: Incyte Corporation is far larger — about 6.5× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 6.17% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Star Bulk Carriers Corp for 24 Days on average.
| INCY | SBLK | |
|---|---|---|
Market Cap | $22.85B | $3.54B |
Volume | 1,927,029 | 1,437,622 |
Sector | Health | Industrials |
52-Week High | $129.93 | $32.49 |
52-Week Low | $83.80 | $16.79 |
Typical Hold Time | 33 Days | 24 Days |
Enterprise Value | $18.35B | $4.22B |
Dividend Yield | — | 6.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Star Bulk Carriers (SBLK) trades at $29.75, up 0.2% today, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals, with Q2 2026 EPS of $1.21 beating estimates by 27% and a 45% year-over-year revenue surge. A $0.90 dividend for H2 2026 reflects robust free cash flow generation. Analyst consensus is strongly positive, with 14 buys out of 24 ratings, supported by recent insider buying activity.
The outlook for SBLK remains favorable due to consistent earnings beats, attractive valuation multiples, and management's commitment to returning capital. Key risks include shipping rate volatility and broader economic sensitivity. The stock presents a compelling opportunity for value and income investors, though exposure to cyclical industry trends warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
